NexStar Pharm(NXTR) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
NexStar Pharm(NXTR)

An SI Board Since December 1996

Posts	SubjectMarks	Bans	Symbol
328	5	0	NXTR

Emcee: Miljenko Zuanic	Type: Unmoderated

Introduction Market Data Compact

To all!

Carently, NXTR is priced at big discaunt comparing the Feb-Aug price. Recently Smith, Montgomery and Vector downgrade NXTR by lowering 1997/98 quoternaly and yearly EPS estimate. It's look like they are more concern about patent despute betwen NXTR-LIPO than real projection of worlwide and US sale of AmBisome and DaunoXome.

Even, with lower grow sale of AmBisome and DaunoXome, NXTR can easily than SEQU and LIPO accept price-war on market(smaler cost of sale and biger accont receivable), it is hard to explane lowering of EPS estimate.

Any other opinion or information on NXTR isue?

Miljenko

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
328	Well, today we have unexpected bad news for NXTR's AmBisome and good news f	Miljenko Zuanic	-	3/20/1999
327	Rob, Chris, and others: Many today (based on NXTR price move) quickly develop	Miljenko Zuanic	-	3/4/1999
326	Assuming that Preveon is effective, I think that there will almost certainly be	Rob-Chemist	-	3/4/1999
325	From PeterSuzman: >Don't forget the excellent results they had for it wi	Chris Boylan	-	3/4/1999
324	Chris, <i>If PREVEON gets approved who is going to use it? </i> D	Biomaven	-	3/4/1999
323	<<This proposed buyout is, at best, poorly timed and ill-conceived.>&	Chris Boylan	-	3/4/1999
322	Chris: <<This proposed buyout is, at best, poorly timed and ill-conceive	Miljenko Zuanic	-	3/4/1999
321	From theStreet.com (RMP): Investors Applaud Gilead's Purchase of NeXstar B	RMP	-	3/2/1999
320	This proposed buyout is, at best, poorly timed and ill-conceived. The company	Chris Boylan	-	3/1/1999
319	Looks like there WAS something to the sudden rise in NexStar last week. Expect	RMP	-	3/1/1999
318	A twenty five percent rise in the last week (from 10 1/4 to 12 3/4), combined w	RMP	-	2/26/1999
317	NXTR accountant needs quick math tuition course (to complete 4Q and 98 results)	Miljenko Zuanic	-	2/23/1999
316	From LIPO 4Q results: <<International sales during the fourth quarter of	Miljenko Zuanic	-	2/10/1999
315	If the speed of the clinical trials for NX211 is like for MiKasome, well, it ma	Miljenko Zuanic	-	2/3/1999
314	Happy New Year to all!	Miljenko Zuanic	-	12/31/1998
313	Presented at ASH: DaunoXome Data Shows Promise in Leukemia, Myeloma; New Data	Miljenko Zuanic	-	12/7/1998
312	Ambisome versus Abelce, and CTLA-4 blocade by mAb for GVHD/GVL (ASH conference)	Miljenko Zuanic	-	11/28/1998
311	Hi Steven: Agree, AR didn't increase significantly for last Q. I will fill	Miljenko Zuanic	-	11/18/1998
310	Miljenko (and other NXTR investors), The 10Q for 98Q3 has come out. We have th	Steven Yang	-	11/18/1998
309	Steven, thanks for reply and note from CC. Before further comments let me cla	Miljenko Zuanic	-	10/24/1998
308	Hello, Miljenko, (continued) MK and other pipeline issues: NXTR has some preli	Steven Yang	-	10/23/1998
307	Hello, Miljenko, Thanks for your comments. I have re-checked my notes from the	Steven Yang	-	10/23/1998
306	Hi Steven: Today report doesn't have to much positive perception. AmBiso	Miljenko Zuanic	-	10/22/1998
305	NXTR Investors: (continued) With the earning report, (and the extra income fro	Steven Yang	-	10/22/1998
304	NXTR investors: NXTR reported its 98Q3 earning this morning. I am glad to note	Steven Yang	-	10/22/1998

Go to reply# or date (mm/dd/yy):